This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Second Look: Comparing 89bio's pegozafermin to Akero's efruxifermin in NASH

Ticker(s): ETNB, AKRO

Who's the expert?

Institution: Imperial College London

  • Clinical Research Fellow and Hepatologist at Imperial College London
  • Current research interest are screening pathways for NAFLD in high risk group patients
  • Sub-investor for several NAFLD and HBV trials

Interview Questions

pegozafermin vs. efruxifermin

Added By: wilson_admin

How do you think the NASH resolution data compares to efruxifermin?

Added By: slingshot_insights

Why do you think efruxifermin has a greater NASH resolution compared to pegozafermin?

Added By: slingshot_insights

Do you believe that weight loss is attributed to differences in the compound, as in the structure, and the PK profile, or to differences in patient baseline?

Added By: slingshot_insights

Pegozafermin had a lower GI toxicity compared to efruxifermin, but efruxifermin's GI toxicity was described as transient and resolving. Do you think there is a difference in the GI toxicity?

Added By: slingshot_insights

I noticed that efruxifermin had three times higher NASH resolution compared to fibrosis improvement than pegozafermin. Should NASH resolution be much higher than fibrosis improvement?

    Added By: slingshot_insights

    The placebo response for pegozafermin was lower for fibrosis than the placebo response for efruxifermin. How would you distinguish using one over the other?

    Added By: slingshot_insights

    Are You Interested In These Questions?

    Slingshot Insights Explained

    Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


    *Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.